Hodgkin LymphomaNCT04396119
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study
An observational study of Hodgkin Lymphoma, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hodgkin Lymphoma
- How many people
- 30 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 11 Feb 2020to 13 Apr 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: Participants who have previously been treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
Who may be able to join
- Details held in the ADAPT database at The Christie NHS Foundation trust
- Responded to most recent ADAPT study questionnaire (April - August 2019)
- Aged 18-80
- Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
- Able to provide informed consent
- Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.
Who cannot join
- Previous or current diagnosis of lung cancer
- Stated within 2019 health questionnaire that they did not wish to be contacted
- Have participated in lung cancer screening through the Manchester Lung Health Checks
Trial locations and contacts
1 site in 1 country.
About this study
To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors
Read the detailed description
Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test
- Conditions
- Hodgkin Lymphoma
- Medical subject headings
- Hodgkin Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Explore survivors' attitudes towards lung cancer and lung cancer screening
Semi-structured interviews
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2020
- Study start11 Feb 2020
- Primary completion13 Apr 2020
- Study completion13 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hodgkin LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Christie NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04396119
- Sponsor's protocol ID
- CFTSp178
- Other IDs
- 276443
- Status last verified
- Sep 2020
- First submitted
- 31 Jan 2020
- Last updated
- 3 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It is not intended to share IPD with other researchers outside the study team
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study
- ClinicalTrials.gov ID
- NCT04396119
- Acronym / sponsor ID
- CFTSp178
- Conditions
- Hodgkin Lymphoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- The Christie NHS Foundation TrustUniversity, hospital or other
- Study start
- 11 Feb 2020 (actual)
- Primary completion
- 13 Apr 2020 (actual)
- Study completion
- 13 Apr 2020 (actual)
- First posted
- 20 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors
Detailed description
Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Participants who have previously been treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
Key inclusion criteria (6 listed)
- Details held in the ADAPT database at The Christie NHS Foundation trust
- Responded to most recent ADAPT study questionnaire (April - August 2019)
- Aged 18-80
- Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
- Able to provide informed consent
Key exclusion criteria (3 listed)
- Previous or current diagnosis of lung cancer
- Stated within 2019 health questionnaire that they did not wish to be contacted
- Have participated in lung cancer screening through the Manchester Lung Health Checks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Explore survivors' attitudes towards lung cancer and lung cancer screening
Time frame: 6 months
Semi-structured interviews
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2020.
- Individual participant dataSharing planned: No. It is not intended to share IPD with other researchers outside the study team
Related trials for Hodgkin Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingObservational study
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
Extranodal NK/T-cell Lymphoma, Nasal Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hodgkin Lymphoma, run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Explore survivors' attitudes towards lung cancer and lung cancer screening (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2020.